Latest News and Press Releases
Want to stay updated on the latest news?
-
BOSTON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with Ocugen, Inc....
-
Histogenics Corporation Announces Adjournment of its Special Meeting to Thursday, September 26, 2019
BOSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it convened and then adjourned, without conducting any...
-
BOSTON, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it intends to convene and then adjourn, without conducting any...
-
BOSTON, Mass. and MALVERN, Penn., April 08, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) and Ocugen, Inc., a privately held clinical-stage biopharmaceutical company focused on...
-
WALTHAM, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), today provided an update on the NeoCart regulatory pathway based on discussions with the U.S....
-
WALTHAM, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
-
WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ‒ Histogenics and FDA Continue Discussions on NeoCart® Phase 3 Data and Potential BLA Submission ‒‒ October 2018 Financing Expected to...
-
WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
-
WALTHAM, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and...
-
WALTHAM, Mass., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the closing of its...